pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection
Merck KGaA, Darmstadt
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt is a pharma organization headquartered in Darmstadt, DE. Primary therapeutic focus areas include Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus, So
Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Frankfurter Str. 250, Darmstadt, 64293, DE
- Employees
- 7,364
- Programs
- 63
- Drugs
- 50
- Patents
- 0
Pembrolizumab
Phase 3 · mab · Triple Negative Breast Neoplasms
Pembrolizumab for Triple Negative Breast Neoplasms is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Internal code 3475-522
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 3
- Modality
- mab
- Indication
- Triple Negative Breast Neoplasms
- Status
- completed
- Trials
- 1